Author

T. Tiganis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 4 Research Focus:differential expression· 4 Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:cell type annotation· 3 Research Focus:cell signaling & trafficking· 2 Approach:statistical model· 2

Frequent Co-Authors

F. Wiede· 3 shared X. Du· 3 shared K.-H. Lu· 2 shared P. Beavis· 2 shared S. Liang· 2 shared Z.-Y. Zhang· 2 shared A. D. Rao· 1 shared A. M. Bennett· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Wiede

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity

S. Liang, E. Tran, X. Du, J. Dong, H. Sudholz, H. Chen, Z. Qu, N. Huntington, J. Babon, N. Kershaw, Z.-Y. Zhang, J. Baell, F. Wiede, T. Tiganis

This study shows that a PTP1B/PTPN2 inhibitor enhances T cell anti-tumor immunity in mice, improves tumor response to PD1 therapy, and avoids immune-related toxicities.

bioRxiv · Jun 16, 2023 · PreprintCancer Biology

Hepatocyte-specific miR-33 deletion attenuates NAFLD-NASH-HCC progression

P. FERNANDEZ TUSSY, J. Sun, M. P. Cardelo, N. L. Price, L. Goedeke, C. E. Xirouchaki, X. Yang, O. Pastor-Rojo, A. M. Bennett, T. Tiganis, Y. Suarez, C. Fernandez-Hernando

This study shows that deleting miR-33 in hepatocytes reduces NAFLD progression to NASH, fibrosis, and HCC by improving lipid metabolism and mitochondrial function.

bioRxiv · Jan 18, 2023 · PreprintPhysiology

PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity

F. Wiede, K.-H. Lu, X. Du, M. Zessig, R. Xu, P. K. Goh, C. Xirouchaki, S. Hogarth, S. Greatorex, K. Sek, R. Daly, P. Beavis, P. Darcy, N. Tonks, T. Tiganis

This study identifies PTP1B as an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity, showing its deletion or inhibition enhances tumor suppression.

bioRxiv · Nov 11, 2021Cancer Biology

RNA binding kinase UHMK1 regulates therapy induced metabolic adaptation in BRAFV600 melanoma

L. K. Smith, T. Parmenter, M. Kleinschmidt, E. P. Kusnadi, J. Kang, C. A. Martin, P. Lau, J. Lorent, A. S. Trigos, T. Ward, A. D. Rao, E. J. Lelliott, K. E. Sheppard, D. Goode, R. J. Hicks, , G. A. McArthur

The paper identifies UHMK1 as a regulator of metabolic adaptation in BRAFV600 melanoma under targeted therapy, showing its role in mRNA transport and translation and its impact on therapy resistance.

bioRxiv · Sep 21, 2019Cancer Biology

PTPN2 deletion in T cells promotes anti-tumour immunity and CAR T cell efficacy in solid tumours

F. Wiede, K.-H. Lu, X. Du, S. Liang, K. Hochheiser, G. Dodd, P. Goh, C. Kearny, D. Meyran, P. Beavis, M. Henderson, S. L. Park, J. Waithman, S. Zhang, Z.-Y. Zhang, , T. Tiganis

This study shows that deleting PTPN2 in T cells improves anti-tumour immunity and CAR T cell effectiveness against solid tumours.

bioRxiv · Sep 5, 2019Immunology